J&D Pharmaceuticals received Orphan Drug Designation awarded by FDA for ADPKD and Progeria.
J & D Pharmaceuticals has developed a lead compound called JD-004 for use in slowing disease progression of ADPKD in patients starting in childhood and continued into adulthood. JD-004 treatment in the animal model of ADPKLD, next to restoring energy metabolism toward wildtype levels, also affected cell proliferation and inflammation. JD-004 positively affected major dysregulated processes in ADPKD: energy metabolism, cell proliferation, and inflammation, providing more insights into its working mechanisms.
The active moiety of JD-004 is effective in slowing the aging process in the animal model associated with Progeria, an accelerated aging disease of children. It is highly likely that when used in the Progeria children (also known as Hutchinson-Gilford Progeria Syndrome/HGPS), JD-004 will be successful in slowing their accelerated aging process.
J & D Pharma has pioneered groundbreaking formulations of intravenous (IV) and oral salicylsalicylic acid phosphatidylcholine (JD-005). These formulations merge the potential efficacy of JD-004 with the well-established gastrointestinal (GI) safety associated with phosphatidylcholine when combined with NSAIDs. Our focus lies in addressing both acute and chronic traumatic brain injury (TBI) scenarios.
Pre-operative, peri-operative, and post-operative analgesic anti-inflammatory treatment is the optimal goal in treating surgical patients. Liposomal JD-005 in intravenous and oral formulations achieves this goal.